Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained marketing approval for the chemical active pharmaceutical ingredients related to Prednisolone Acetate from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.
The drug is mainly used to treat allergic and autoimmune inflammatory diseases.